ANX007: Clinical Trials

2 completed, 1 active not recruiting, 1 not yet recruiting. 2 Phase 3, 1 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	2	Active not recruiting 1, Not yet recruiting 1
Phase 1	1	Completed 1
Phase 2	1	Completed 1

Follow ANX007: new trials by email Literature Review of ANX007 trials Research Report on ANX007

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) Vonaprument - Geographic Atrophy	Phase 3	Not yet recruiting	Annexon, Inc.	605	2026-09-30	2026-09-08
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) Vonaprument, Sham Administration - Geographic Atrophy	Phase 3	Active not recruiting	Annexon, Inc.	659	2024-07-30	2026-10-06
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy ANX007, Sham comparator - Geographic Atrophy	Phase 2	Completed	Annexon, Inc.	270	2021-02-26	2026-10-21
Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma ANX007 - Open-angle Glaucoma	Phase 1	Completed	Annexon, Inc.	9	2018-03-23	2020-08-20

Conditions studied

Geographic Atrophy (3)  ·  Glaucoma, Open-Angle (1)

Sponsors

Annexon, Inc. (4)

Countries

United States (4)  ·  Australia (2)  ·  New Zealand (2)  ·  Austria (1)  ·  Canada (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Hungary (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Eric Humphriss (1)

Results publications

PMID 37314061